http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유방암에서 Insulin-like Growth Factor Binding Protein (IGFBP)-3 및 PTEN 발현의 감소와 임상병리학적 소견과의 관련성
정성후(Sung Hoo Jung),윤현조(Hyun Jo Youn),김민선(Min Sun Kim),김선영(Sun-Young Kim),황평한(Pyoung Han Hwang),이대열(Dae-Youl Lee) 대한외과학회 2010 Annals of Surgical Treatment and Research(ASRT) Vol.79 No.2
Purpose: Insulin-like growth factor binding protein (IGFBP-3) and phosphatase and tensin homolog (PTEN) are tumor-suppressor genes that may be involved in breast tumorigenesis. However, the roles of these genes in the regulation of breast cancer growth or progress are unclear. In this study, we aimed to find any correlation between the reduction of IGFBP-3 or PTEN protein expression in cancer tissues and the clinicopathological parameters in breast cancer. Methods: We collected both cancer and adjacent normal tissues from 46 breast cancer patients (from January 1 to December 31, 2006), and checked the IGFBP-3 and PTEN protein levels in cancer and adjacent normal tissues using Western immunoblot. We evaluated the correlation of reduction status of IGFBP-3 and PTEN protein expression with variable clinicopathological parameters. Results: The frequency of IGFBP-3 and PTEN protein reduction in cancer tissue, compared to adjacent normal tissue, was 63.0% and 34.8%, respectively. And in 87.5% of patients, who showed significant PTEN reduction, IGFBP-3 protein expression was reduced in cancer tissues. In contrast, IGFBP-3 protein reduced in only 50% of patients who didn’t show PTEN reduction. However, we did not find any significant correlation between reduction of IGFBP-3 or PTEN expression in cancer tissue and variable clinicopathological parameters. Conclusion: The IGFBP-3 and PTEN genes were expressed in all breast cancer tissues. Nonetheless, we did not find any significant relationship between reduction of IGFBP-3 or PTEN expression and the clinicopathological parameters in this study. Therefore, further studies are needed to document the roles of IGFBP-3 and PTEN genes in breast cancer growth or progress.
갑상선 선종을 동반한 원발성 부갑상선 기능 항진증 1예
정성후(Sung Hoo Jung),김완철(Wan Cheol Kim),강남부(Nam Poo Kang) 대한두경부종양학회 1999 대한두경부 종양학회지 Vol.15 No.1
Primary hryperparathyroidism is a relatively rare disease entity in Korea. It's characterized by severe skeletal and renal changes due to hypersecretion of parathyroid hormone, and rarely shows peptic ulceration, hypertension, pancreatitis and impaired mentality. Recently the determination of the serum calcium level has become a routine laboratory test and the awareness of primary hyperparathyroidism has been incerased, the disease is being diagnosed with increasing frequency. Primary hyperparathyroidism is most commonly caused by parathyroid adenoma and rarely hyperplasia, cancer of parathyroid glands. The authors operated sucessfully a case of primary parathyroid adenoma by diagnosed by nuclear medical diagnostic work-up. The patient had anterior neck mass(soft, non tender nodule) on physical examination, multiple goiter on thyroid ultrasonogram and scan. The parathyroid lesion was difficult to find preoperatively.
정성후,Sung Hoo Jung,M,D 대한갑상선-내분비외과학회 2002 The Koreran journal of Endocrine Surgery Vol.2 No.1
Purpose: Thyroid cancer is the most common endocrine malignancy, and it has a wide spectrum of biologic behavior, histologic appearance, and management. This study reviewed various aspects of the clinical features of differentiated thyroid cancer. Methods: We retrospectively reviewed the clinical characteristics of 114 patients who had undergone surgical management for differentiated thyroid cancer at the Chonbuk National University Hospital from September 1989 to December 1997. Results: The most prevalent age group was in the 5th decade (29 cases, 25.4%). The male-to-female ratio was 1 to 5.7. The most common initial symptom was a palpable mass on the anterior or the lateral portion of the neck (110 cases, 96.5%). The most common duration of illness from the appearance of the symptom to the treatment was below 3 months (38 cases, 34.5%). The primary tumors were located on the right lobe (49 cases, 43.0%), the left lobe (38 cases, 33.3%), both lobes (22 cases, 19.3%), and the isthmus (5 cases, 4.4%). In the histopathologic study, the common type was a papillary carcinoma (102 cases, 89.5%). The common surgical procedures were a total thyroidectomy (66 cases, 57.8%) and a near total thyroidectomy (24 cases, 21.0%). Seventy-five patients (65.8%) received a lymph-noe dissection, and there was cervical lymph-node metastasis in 43 cases (57.3%) of this group. Postoperative complications occurred in 11 cases (9.3%). The common complications were hemorrhage or seroma (5 cases, 4.4%), hoarseness (5 cases, 4.4%) and wound infection (1 cases, 0.9%). Although hypoparathyroidism was predicted, the predominant symptoms did not appear. Regional recurrence or distant metastases were present in 13 cases (11.4%) during four years. Conclusion: Thyroid cancer has a wide sectrum of biological behavior and also problems including the lack of reliable prognostic factors and objective assessments of therapeutic modalities. Appropriate and aggressive management should be recommended because most of differentiated thyroid cancer has a favorable prognosis. (Korean J Endocrine Surg 2002;2:19-24)
갑상선 분화암 수술 후 저용량 방사성 옥소(I-131)요법
정성후,정연준,유희철,강남부,Sung Hoo Jung,M,D,Yeon Jun Jeong,M,D,Hee Chul Yu,M,D,and Nam Poo Kang,M,D 대한갑상선-내분비외과학회 2001 The Koreran journal of Endocrine Surgery Vol.1 No.1
Purpose: To assess the effectiveness of low-dose (30 mCi) I-131 ablation therapy for remnant thyroid tissue following total thyroidectomy for differentiated thyroid cancer. Methods: Between March 1995 and December 1997, 48 patients were given ablative doses (30 mCi) of I-131 following total thyroidectomy for differentiated thyroid cancer in the presence of I-131 uptake in remnant thyroid tissue. The effective ablation of remnant thyroid tissue was determined using a subsequent I-131 whole body scan. If any remnant thyroid tissue remained, we repeated the same management protocol at 6-month intervals. Results: Thirty-eight (79.1%) patients displayed papillary, 8 (16.7%) follicular, 1 (2.1%) medullary and 1 (2.1%) Hurthle cell type cancer. Forty-eight patients underwent total thyroidectomy, 35 cases of which underwent central neck dissection, and 14 cases modified radical neck dissection. Postoperative complication developed in 8 cases, including 4 cases of transient hypoparathyroidism, 1 case of permanent hypoparathyroidism, 2 cases of transient recurrent laryngeal nerve palsy, and 1 case of wound hematoma. There was significant remnant thyroid tissue detected in 46 cases (95.8%) following total thyroidectomy, which were able to be ablated by low dose (30 mCi) I-131. There was no statistical difference between the operative procedures or the numbers of treatment of I-131. Conclusion: This data suggests that low-dose (30 mCi) I- 131 therapy is effective for the ablation of remnant thyroid tissue following total thyroidectomy for differentiated thyroid cancer. (Korean J Endocrine Surg 2001;1:98-103)
갑상선 유두암에서 전이 림프절 비율의 예후 인자적 가치
강상율(Sang Yull Kang),김선광(Seon Kwang Kim),윤현조(Hyun Jo Youn),정성후(Sung Hoo Jung) 대한갑상선-내분비외과학회 2015 The Koreran journal of Endocrine Surgery Vol.15 No.3
Purpose: Metastatic lymph node ratio (MLNR) is known as an important prognostic factor in many solid carcinomas; however, the role of MLNR in papillary thyroid carcinoma (PTC) is unclear. The purpose of this study was to determine whether MLNR has prognostic significance for recurrence in patients with pathological N1a PTC. Methods: A retrospective analysis was conducted of 1,198 patients with PTC who underwent total thyroidectomy with central neck dissection between 2006 and 2011. Only patients with central lymph node metastasis were included in this study. Patients with lateral neck lymph node metastasis or extrathyroidal involvement were excluded. Finally, this study included 282 patients with N1a patients. MLNR was defined as the number of metastatic lymph nodes divided by the number of removed lymph nodes. Results: Median age was 47.3 years (17∼73 years). There were 209 female patients and 41 male patients, respectively. Median follow-up period was 53 months (36∼114 months). Median value of MLNR was 0.36 (0.04∼1.000). Of 250 patients, 20 patients (8.0%) developed recurrent disease. MLNR independently predicted PTC recurrence (odds ratio [OR], 6.385; 95% confidence interval [CI], 2.523-16.158; P < 0.001). In receiver operating characteristic curve analysis, 0.47 was significantly meaningful for recurrence when three or more lymph nodes were collected. Conclusion: MLNR is an independent predictor of PTC recurrence in patients with pathological N1a PTC. Therefore, N1a patients with MLNR > 0.47 should be monitored closely for recurrence.